Related U.S. Application Data 3 страница

US 9, 539, 210 B2

Page 8

(56) References Cited

OTHER PUBLICATIONS

Khandare, et al., “Polymer-drug conjugates: Progress in polymeric prodrugs, ” Progress in Polymer Science, 31(4): 359-397 (2006).

Kim, et al., “Target-specific cellular uptake of PLGA nanoparticies coated with poly(L-lysine)-poly(ethyleneglycol)-folate conjugate”, Langmuir, 21(19): 8852-8857 (2005).

Knight, et al., “Hydrodynamic Focusing on a Silicon Chip: Mixing Nanoliters in Microseconds”, Phys. Rev. Lett., 80: 3863-3866 (1998).

Koenig, et al., “Immunologic factors in human milk: the effects of gestational age and pasteurization”, J Human Lactation, 21: 439-43 (2002).

Koivunen, et al., “Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. ”, Biotechnology (NY), 13(3): 265-270 (1995).

Koivunen, et al., “Tumor targeting with a selective gelatinase inhibitor”, Nat. Biotechnol., 17: 768-774 (1999).

Konan, et al., “Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticies for photodynamic therapy”, Eur. J. Pharmaceutics Biopharmaceutics, 55: 115-124 (2003).

Kozikowski, et al., “Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. ”, J. Med. Chem., 47(7): 1729-1738 (2004).

Kreitman, et al., “Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. ”, N. Engl J. Med., 345(4): 241-347 (2001).

Kreitman, et al., “Phase I trial of recombinant immunotoxin anti- Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. ”, J. Clin. Oncol., 18(8): 1622-1636 (2000).

Krieg, et al., “CpG motifs in bacterial DNA trigger direct B-cell activation. ”, Nature, 374(6522): 546-549 (1995).

Kukowska-Latallo, et al., “Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers”, Proc. Natl. Acad. Sci., USA, 93(10): 4897-4902 (1996).

Kumar, et al., “Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. ”, Cancer Res., 61(5): 2232-2238 (2001).

Kwon, et al., “Pseudopoly(amino acids): A study of the synthesis and characterization of poly(acyl-hydroxyproline-esters)”, Macromolecules, 22: 3250-3255 (1989).

Kohrer, et al., “Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. ”, Nucleic Acids Res., 32(21): 6200-6211 (2004).

Kohrer, et al., “Import of amber and ochre suppressor tRNAs into mammalian cells: a general approach to site-specific insertion of amino acid analogues into proteins. ”, Proc. Natl. Acad. Sci., USA, 98(25): 14310-14315 (2001).

Kohrer and Rajbhandary, “Proteins carrying one or more unnatural amino acids, ” In Ibba, et al., (eds. ), Aminoacyl-tRNA Synthetases, Landes Bioscience, Chapter 31 (2005).

Laakkonen, et al., “Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. ”, Proc. Natl. Acad. Sci., USA, 101(25): 9381-9386 (2004).

Labhasetwar, et al., “Arterial uptake of biodegradable nanoparticies: Effect of surface modifications, ” J. Pharm. Sci., 87(10): 1229-34 (1998).

Lamalle-Bernard, et al., “Coadsorption of HIV-1 p24 and gpl20 proteins to surfactant-free anionic PLA nanoparticies preserves antigenicity and immunogenicity”, J Control Rel., 115(l): 57-67 (2006).

Langer, “Biomaterials in drug delivery and tissue engineering: one laboratory’s experience. ”, Acc. Chem. Res., 33(2): 94-101 (2000).

Langer, “New methods of drug delivery, ” Science, 249(4976): 152733 (1990).

Langer, “Selected advances in drug delivery and tissue engineering”, J. Control. Release, 62: 7-11 (1999).

Langone, et al., “Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine”, Biochem., 12(24): 5025-5030 (1973).

Langone & Van Vunakis, “Radioimmunoassay of Nicotine, Cotinine, and ³-(3-Pyridyl)-³-oxo-N-methylbutyramide”, Met. Enzymol., 84: 628-640 (1982).

Leamon, et al., “Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. ”, J. Biol. Chem., 268(33): 24847-24854 (1993).

Leamon, et al., “Selective targeting of malignant cells with cytotoxin-folate conjugates. ”, J. Drug Target., 2(2): 101 -112 (1994). Lee, et al. “Adaptations of Nanoscale Viruses and Other Protein Cages for Medical Applications” Nanomedicine-Nanotechnology Biology and Medicine. 2(3): 137-149 (2006).

Lehr, “Lectin-mediated drug delivery: The second generation of bioadhesives”, J. of Controlled Release, 65: 19-29 (2000).

Leopold, et al., “Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. ”, Human Gene Therapy, 9(3): 367-378 (1998).

Leroy, et al., “Radioimmunodetection of lymph node invasion in prostatic cancer. The use of iodine 123 (123I)-labeled monoclonal anti-prostatic acid phosphatase (PAP) 227 A F(ab')2 antibody fragments in vivo. ”, Cancer, 64(1): 1-5 (1989).

Leucuta, et al., “Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects, ” International Journal of Pharmaceutics, 41: 213-7 (1988). Lim, et al., “A Self-Destroying Polycationic Polymer: Biodegradable Poly(4-hydroxy-I-proline ester)”, J. Am. Chem. Soc., 121(24): 5633-5639 (1999).

Lim, et al., “Cationic hyperbranched poly(amino ester): a novel class of DNA condensing molecule with cationic surface, biodegradable three-dimensional structure, and tertiary amine groups in the interior. ”, J. Am. Chem. Soc, 123(10): 2460-2461 (2001).

Lim et al., “Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan”, J. of Controlled Release, 66: 281-292 (2000).

Lin, et al., “AmicroRNApolycistron as a potential human oncogene p828”, Nature, 435(7043): 828-833 (2005).

Lin, et al., “Well-Ordered Mesoporous Silica Nanoparticies as Cell Markers”, Chem. Mater., 17: 4570-4573 (2005).

Liu, et al., “Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen”, The Prostate, 68(9): 955-964 (2008).

Liu, et al., “Constitutive and antibody-induced internalization of prostate-specific membrane antigen. ”, Cancer Res., 58(18): 4055- 4060 (1998).

Liu, et al., “Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. ”, J. Drug Target., 7: 43-53 (1999).

Liu, et al., “Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer”, The Prostate, 68(4): 418- 426 (2008).

Liu, et al., “Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. ”, Cancer Res., 57(17): 3629-3634 (1997).

Low, et al., “Folate receptor-targeted drugs for cancer and inflammatory diseases. ”, Adv. Drug Deliv. Rev., 56(8): 1055-1058 (2004). Lu, et al., “MicroRNA expression profiles classify human cancers”, Nature, 435(7043): 834-838 (2005).

Ludewig, et al., “Induction of optimal anti-viral neutralizing В cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. ”, Eur. J. Immunol., 30(l): 185-196 (2000).

Lupoid, et al., “Identification and characterization of nuclease- stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. ”, Cancer Res., 62(14): 4029-4033 (2002).

Lyu, et al., “The immunocytokine scFv23/TNF sensitizes HER-2/ neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-L”, Mol. Cancer Ther., 4(8): 1205-1213 (2005).

Maher, “DNA triple-helix formation: An approach to artificial gene repressors? ”, Bioassays 14: 807-815 (1992).

US 9, 539, 210 B2

Page 9

(56) References Cited

OTHER PUBLICATIONS

Majer, et al., “Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCPII inhibitor. ”, J. Med. Chern., 46(10): 1989-1996 (2003). Manolova, et al., “Nanoparticles target distinct dendritic cell populations according to their size”, Eur. J. Immunol., 38: 1404-1413 (2008).

Manz, et al., “Capillary electrophoresis on a chip”, J. Chromatography, 593: 253-258 (1992).

Martin, et al., “Crystal structure at 2. 8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. ”, Mol Cell, 7: 867-77 (2001).

Mathiowitz, et al., “Novel microcapsules for delivery systems”, Reactive Polymers, 6: 275-283 (1987).

Mathiowitz, et al., “Polyanhydride Microspheres as Drug Carriers. II.. Microencapsulation by Solvent Removal”, J. Appl. Polymer Sei., 35: 755-774 (1988).

Mathiowitz, et al., “Polyanhydride Microspheres as Drug Carriers I. Hot Melt Encapsulation”, J. Control. Release, 5: 13-22 (1987).

Matsuo, et al., “Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides”, Biochem Biophys Res Commun., 362: 1069-72 (2007).

Mattheakis, et al., “Optical coding of mammalian cells using semiconductor quantum dots. ”, Analytical Biochemistry, 327(2): 200-208 (2004).

Maung, et al., “Probing for a hydrophobic a binding register in prostate-specific membrane antigen with

phenylalkylphosphonamidates. ”, Bioorg. Med. Chem., 12(18): 4969-4979 (2004).

McDevitt, et al., “An alpha-particle emitting antibody ([213Bi] J591) for radioimmunotherapy of prostate cancer. ”, Cancer Res., 60(21): 6095-6100 (2000).

McDevitt, et al., “Tumor therapy with targeted atomic nanogenerators. ”, Science, 294(5546): 1537-1540 (2001).

McNeil, “Nanotechnology for the biologist”, J. Leukoc Biol., 78: 575-94 (2005).

Mead, et al., “Laboratory vector competence of black flies (Diptera: Simuliidae) for the Indiana serotype of vesicular stomatitis virus. ”, Ann. N. Y. Acad. Sei., 916: 437-443 (2000).

Meister, et al., “Mechanisms of gene silencing by double-stranded RNA. ”, Nature, 431(7006): 343-349 (2004).

Melani, et al., “Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. ”, Cancer Res., 58(18): 4146-4154 (1998).

Mempel, et al., “T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. ”, Nature, 427(6970): 154-159 (2004). Metelitsa, et al., “Antidisialoganglioside/granulocyte macrophagecolony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CDllb/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. ”, Blood, 99(11): 4166-4173 (2002).

Meyers, et al., “Development of monoclonal antibody imaging of metastatic prostatic carcinoma. ”, Prostate, 14(3): 209-220 (1989).

Milligan and Uhlenbeck, “Synthesis of small RNAs using T7 RNA polymerase, ” Methods in Enzymology, 180: 51-62 (1989).

Mitra, et al., “Tumour targeted delivery of encapsulated dextrandoxorubicin conjugate using chitosan nanoparticles as carrier”, J Controlled Release, 74: 317-23 (2001).

Mi, et al., “Release of Indomethacin from a Novel Chitosan Microsphere Prepared by a Natrually Occurring Crosslinker: Examination of Crosslinking and Polycation-Anionic Drug Interaction”, J. of Applied Polymer Science, 81: 1700-1711 (2001).

Moghimi, et al., “Long-circulating and target-specific nanoparticles: theory to practice, ” Pharmacol. Rev., 53(2): 283-318 (2001).

Moon, et al., “Engineering Nano- and microparticles to tune immunity”, Adv Mater., D01: 10. 1002/adma. 201200446 (2012).

Mulligan, “The basic science of gene therapy, ” Science, 260(5110): 926-32 (1993).

Murphy, et al., “Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. ”, J. Urol., 160(6 Pt 2): 2396-2401 (1998).

Murray, et al., “Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies”, Ann. Rev.

Mat. Sei., 30: 545-610 (2000).

Myers and Miller, Optimal alignments in linear space, CABIOS, 4(1): 11-17 (1988).

Nan, et al., “Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. ”, J. Med. Chem., 43(5): 772-774 (2000).

Neidle, “The molecular basis for the action of some DNA-binding drugs”, Prog. Med. Chem., 16: 151-221 (1979).

Nguyen and Wu, “Micromixers a review. ”, J. Micromechan. Microeng., 15: R1 (2005).

Notter, et al., “Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. ”, Blood, 97(10): 3138-3145 (2001).

O’Donnell, et al., “с-Мус-regulated microRNAs modulate E2F1 expression, ” Nature, 435(7043): 839-843 (2005).

Ochsenbein, et al., “Control of early viral and bacterial distribution and disease by natural antibodies. ”, Science, 286(5447): 2156-2159 (1999).

Ochsenbein, et al., “Protective T cell-independent antiviral antibody responses are dependent on complement. ”, J. Exp. Med., 190(8): 1165-1174 (1999).

Okada, et al., “Antigen-engaged В cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. ”, PLoS Biol., 3(6): el50 (2005).

Oliver, et al., “Conformational and SAR analysis of NAALADase and PSMA inhibitors. ”, Bioorg. Med. Chem., ll(20): 4455-4461 (2003).

Olivier, et al., “Drug Transport to Brain with Targeted Nanoparticles”, J. of the Am. Society of Experimental Neuro Therapeutics, 2: 108-119 (2005).

Oyewumi, et al., “Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice”, J Control Rel., 93: 613-26 (2004).

Oyewumi, et al., “Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses”, Exp Rev Vaccines, 9(9): 1095-1107 (2010).

Pape, et al., “The humoral immune response is initiated in lymph nodes by В cells that acquire soluble antigen directly in the follicles. ”, Immunity, 26(4): 491-502 (2007).

Papisov, “Acyclic Polyacetals from Polysaccharides: Biomimetic Biomedical “Stealth” Polymers”, ACS Symposium Series, 786: 301314 (2001).

Parekh, et al., “Biomarkers for Prostate Cancer Detection”, The Journal of Urology, 178(6): 2252-2259 (2007).

Pasqualini, et al., “Aminopeptidase N is a receptor for tumorhoming peptides and a target for inhibiting angiogenesis. ”, Cancer Res., 60(3): 722-727 (2000).

Patri, et al., “Synthesis and in Vitro Testing of J591 Antibody Dendrimer Conjugates for Targeted Prostate Cancer Therapy”, Bioconj. Chem., 15: 1174-1181 (2004).

Pellegrino, et al., “On the development of colloidal nanoparticles towards multifunctional structures and their possible use for biological applications. ”, Small, l(l): 48-63 (2005).

Pfohl, et al., “Trends in microfiuidics with complex fluids. ”, Chemphyschem, 4(12): 1291-1298 (2003).

Phillips, et al., “Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production. ”, Vaccine, 10(3): 151-158 (1992).

Pimentel, et al., “Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine”, Chemical Biology & Drug Design, 73(1): 53-61 (2009).

Ponchel, et al., “Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract”, Advanced Drug Delivery Reviews, 34: 191-219 (1998).

US 9, 539, 210 B2

Page 10

(56) References Cited

OTHER PUBLICATIONS

Porkka, et al., “A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. ”, Proc. Natl. Acad. Sci., USA, 99(ll): 7444-7449 (2002).

Putnam, et al., “Poly(4-hydroxy-l-proline ester): Low-Temperature Polycondensation and Plasmid DNA Complexation”, Macromolecules, 32(11): 3658-3662 (1999).

Qi, et al., “Extrafollicular activation of lymph node В cells by antigen-bearing dendritic cells”, Science, 312(5780): 1672-1676 (2006).

Quintanar-Guerrero, et al., “Preparation Techniques and Mechanisms of Formation of Biodegradable Nanoparticles from Preformed Polymers”, Drug Dev. Industrial Pharmacy, 24(12): 1113- 1128 (1998).

Reddy, et al., “Exploiting lymphatic transport and complement activation in nanoparticle vaccines”, Nat. Biotech., 25(10): 1159- 1164 (2007).

Reif, et al., “Balanced responsiveness to chemoattractants from adjacent zones determines В-cell position. ”, Nature, 416(6876): 94- 99 (2002).

Reiher, et al., “Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. ”, Int. J. Cancer, 98(5): 682-689 (2002).

Reubi, et al., “Peptide receptors as molecular targets for cancer diagnosis and therapy. ”, Endocr. Rev., 24(4): 389-427 (2003).

Reynolds, et al., “Rational siRNA design for RNA interference. ”, Nat. Biotechnol., 22(3): 326-330 (2004).

Riley, et al., “Physicochemical evaluation of nanoparticles assembled from Poly(lactic acid)-Poly(ethylene glycol) (PLA_ PEG) block copolymers as drug delivery vehicles”, Langmuir, 17: 3168-74 (2001).

Riley, et al., “Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles”, Colloids Surfaces В Biointerfaces, 16: 147-59 (1999).

Robbins, et al., “Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro”, Nature Biotechnology, 24(5): 566-571 (2006).

Robinson, et al., “LEAPT: lectin-directed enzyme-activated prodrug therapy. ”, Proc. Natl. Acad. Sci., USA, 101(40): 14527-14532 (2004).

Roost, et al., “Mapping of the dominant neutralizing antigenic site of a virus using infected cells. ”, J. Immunol. Methods, 189(2): 233- 242 (1996).

Rossbacher and Shlomchik, “The В cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance В cell immune responses in vivo. ”, J. Exp. Med., 198(4): 591-602 (2003).

Sampson, et al., “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. ”, J. Neurooncol., 65(l): 27-35 (2003).

Santoyo, et al., “Highly specific and accurate selection of siRNAs for high-throughput functional assays. ”, Bioinformatics, 21(8): 1376-1382 (2005).

Sarkar, et al., “Ligand-DNA interaction in a nanocage of reverse micelle”, Biopolymer., 83(6): 675-86 (2006).

Sarver, et al., “Ribozymes as potential anti-HIV-1 therapeutic agents. ”, Science 247(4947): 1222-1225 (1990).

Schally, et al., “Peptide analogs in the therapy of prostate cancer. ”, Prostate, 45(2): 158-166 (2000).

Schultz, et al., “Single-target molecule detection with nonbleaching multicolor optical immunolabels. ”, Proc. Natl. Acad. Sci., USA, 97(3): 996-1001(2000).

Schultz, “Plasmon resonant particles for biological detection”, Curr. Op. Biotechnol., 14: 13-22 (2003).

Shaida, et al., “Expression of BNIP3 correlates with hypoxiainducible factor (HIF)-la, HlF-2a and the androgen receptor in

prostate cancer and is regulated directly by hypoxia but not androgens in cell lines”, The Prostate, 68(3): 336-343 (2008).

Shen, et al., “Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles”, Immunol., 117: 78-88 (2006).

Shestopalov, et al., “Multi-step synthesis of nanoparticles performed on millisecond time scale in a microfluidic droplet-based system. ”, Lab on a Chip, 4(4): 316-321 (2004).

Shields, et al., “High resolution mapping of the binding site on human IgGl for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgGl variants with improved binding to the Fc gamma R”, J Biolo Chem., 276(9): 6591-6604 (2001).

Shim, “One target different effects: a comparison of distinct therapeutic antibodies against the same targets”, Exp Mole Med. , 43(10): 539-49 (2011).

Shimoda, et al., “Bioadhesive Characteristics of Chitosan Mircroshperes to the Mucosa of Rat Small Intestine”, Drug Delvelopment and Inustrial Pharmacy, 27(6): 567-576 (2001).

Shiow, et al., “CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. ”, Nature, 440(7083): 540-544 (2006).

Silver, et al., “Prostate-specific membrane antigen expression in normal and malignant human tissues. ”, Clin. Cancer Res., 3(1): 81 - 85 (1997).

Simberg, et al., “Biomimetic amplification of nanoparticle homing to tumors”, Nat\l. Acad. Sic. USA, 104(3): 921-936 (2007).

Smith-Jones, et al., “In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostatespecific membrane antigen. ”, Cancer Res., 60(18): 5237-5243 (2000).

Sondel, et al., “Preclinical and clinical development of immunocytokines. ”, Curr. Opin. Investig. Drugs, 4(6): 696-700 (2003).

Song, et al., “A Microfluidic System for Controlling Reaction Networks in Time”, Angewandte Chemie—Int’l Ed., 42: 768-772 (2003).

Spooner, et al., “Anovel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. ”, Br. J. Cancer, 88(10): 1622-1630 (2003).

Stoermer, et al., “Synthesis and biological evaluation of hydroxam- ate-Based inhibitors of glutamate carboxypeptidase II. ”, Bioorg.

Med. Chem. Lett., 13(13): 2097-2100 (2003).

Storm, et al., “Surface Modification of Nanoparticles to Oppose Uptake by the Mononuclear Phagocyte System”, Adv. Drug Deliv. Rev., 17: 31-48 (1995).

Stroock, et al., “Chaotic mixer for microchannels. ”, Science, 295(5555): 647-651 (2002).

Sutcliffe, et al., “Antibodies that react with predetermined sites on proteins”, Science, 219: 660-666 (1983).

Suzuki, et al., “Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy”, Yakugaku Zasshi, 127(2): 301-6 (2007). English Abstract.

Takeuchi, et al., “Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes”, Pharmaceutical Research, 13(6): 896-901 (1996).

Takeuchi, et al., “Spray-Dried Lactose Composite Particles Containing an Ion Complex of Alginate-Chitosan for Desinging a Dry-Coated Tablet Having a Time-Controlled Releasing Function”, Pharmaceutical Research, 17 (l): 94-99 (2000).

Takeuchi et al., “Mucoadhesive Lipsomes Coated with Chitosan or Carbopol for Oral Administration of Peptide Drugs”, Proceed. Inti.

Symp. Control. Rel. Bioact. Mater., 26: 988-989 (1999).

Tang, et al., “In Vitro Gene Delivery by Degraded Polyamidoamine Dendrimers”, Bioconjugate Chem., 7: 703-714 (1996).

Tang, et al., “Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. ”, Biochem. Biophys. Res. Com- mun, 307(l): 8-14 (2003).

Tavitian, et al., “In vivo imaging with oligonucleotides for diagnosis and drug development”, Gut, 52 Su, I IV: 40-47 (2003).

Taylor, et al., “Development of a specific system for targeting protein to metallophilic macrophages”, PNAS, 101(7): 1963-8 (2004).

US 9, 539, 210 B2

Page 11

(56) References Cited

OTHER PUBLICATIONS

Taylor, et al., “Macrophage receptors and immune recognition. ”, Annu. Rev. Immunol., 23: 901-944 (2005).

Tindall, et al., “The Rationale for Inhibiting 5a-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer”, The Journal of Urology, 179(4): 1235-1242 (2008).

Tobio, et al, “Role of PEG on the stability in digestive fluids and in vivo fate of PEG-PL A nanoparticies following oral administration”, Colloids and Surfaces B: Biointerferences, 18: 315-323 (2000). Tomai, et al., “Resiquimod and other immune response modifiers as vaccine adjuvants”, Expert Rev Vaccines, 6: 835-847 (2007) Abstract Only.

Trindade, et al., “Nanocrystalline Semiconductors: Synthesis, Properties, and Perspectives”, Chem. Mat., 13(11): 3843-3858 (2001).

Tsukamoto, et al., “Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate, potent inhibitors of glutamate carboxypeptidase II. ”, Bioorg. Med. Chem. Lett., 12(16): 2189-2192 (2002).

Uhrich, et al., “Polymeric Systems for Controlled Drug Release”, Chem. Rev., 99(11): 3181-3198 (1999).

Unkeless, et al., “Structure and function of human and murine receptors for IgG. ”, Annu. Rev. Immunol., 6: 251-281 (1998).

Uto, et al., “Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticies induces antigen-specific humoral and cellular immunity”, J Immunology, 178(5): 2979-86 (2007).

Uwatoku, et al., “Application of Nanoparticle Technology for the Prevention of Restenosis After Balloon Injury in Rats, ” Circ. Res., 92(7): e62-9 (2003).

Valentini, et al., “Association of anthracycline derivatives with DNA: a fluorescence study. ”, Farmaco [Sci], 40: 377-390 (1985).

Vallabhajosula, et al., “Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. ”, Prostate, 58(2): 145-155 (2004).

Vascotto, et al., “Antigen presentation by В lymphocytes: how receptor signaling directs membrane trafficking. ”, Curr., Opin., Immunol., 19(l): 93-98 (2007).

Vihko, et al., “Radioimaging of Prostatic Carcinoma With Prostatic Acid Phosphatase—Specific Antibodies”, Biotechnology in Diagnostics, 131-134 (1985).

Vila, et al., “Design of biodegradable particles for protein delivery”, Journal of Controlled Release, 78: 15-24 (2002).

Vila, et al., “PLA-PEG Nanospheres: New Carriers for Transmucosal Delivery of Proteins and Plasmid DNA”, Poly. Adv. Technol., 13: 851-858 (2002).

Villa, et al., “PLA-PEG particles as nasal protein carriers: the influence of the particle size”, Int. J Pharmaceut., 292: 43-52 (2005). Von Allmen, et al., “V domain of RAGE interacts with AGEs on prostate carcinoma cells”, The Prostate, 68(7): 748-758 (2008).

Von Andrian and Mempel, “Homing and cellular traffic in lymph nodes. ”, Nat. Rev. Immunol., 3(11): 867-878 (2003).

Wakita, et al., “An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen”, Int. Immunol., 18(3): 425-34 (2006).

Wang, et al., “A novel biodegradable gene carrier based on polyphosphoester. ”, J. Am. Chem. Soc., 123(38): 9480-9481 (2001). Wang, et al., “Autoantibody signatures in prostate cancer. ”, N Engl J Med, 353(12): 1224-1235 (2005).

Wang, et al., “Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. ”, Int. J. Cancer, 92(6): 871-876 (2001).

Wang, et al., “Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1. 2-A resolution. ”, Biochemistry, 26(4): 1152-1163 (1987).

Weaver, et al., “Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. ”, J. Neurooncol., 65(1): 3-13 (2003).

Wessels, et al., “Studies of group В streptococcal Infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. ”, Proc. Natl. Acad. Sci., USA, 92(25): 11490-11494 (1995).

Whelan, et al., “Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. ”, Proc. Natl. Acad. Sci., USA, 92(18): 8388-8392 (1995).

Wilson, et al., “The Structure of an Antigenic Determinant in a Protein”, Cell, 37: 767-778 (1984).

Wind, et al., “An integrated confocal and magnetic resonance microscope for cellular research. ”, J. Magn. Reson., 147(2): 371-377 (2000).

Wlotzka, et al., “In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class, ” Proc. Natl. Acad. Sci. U. S. A., 99(13): 8898-902 (2002).

Wright, et al., “Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. ”, Blood, 97(8): 2278-2285 (2001).

Wu, et al., “Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. ”, Nat. Biotechnol., 21(l): 41-46 (2003).

Wu, et al., Selection of oligonucleotide apatamers with enhanced uptake and activation of human leukemia В cells,, Human Gene., 14: 849-860 (2003).

Wu, “Arming antibodies: prospects and challenges for immunoconjugates. ”, Nat. Biotechnol., 23(9): 1137-1146 (2005).

Yamada, et al., “In Vitro and in Vivo Evaluation of Sustained Release Chitosan-Coat Ketoprofen Microparticles”, Yakugaku Zasshi, 121(3): 239-245 (2001).

Yang, et al., “Micelles formed by self-assmbling of polylactide(ethylene glycol) block copolymers in aqueous solutions”, J Colloid Interfac Si., 314: 470-77 (2007).

Yang, “Imaging of vascular gene therapy. ”, Radiology, 228: 36-249 (2003).

Yoo, et al., “In vitro and in vivo anti-tumor activities of nanoparticies based on doxorubicin-PLGA conjugates. ”, J. Control. Release, 68(3): 419-431 (2000).

Yourong, et al, “Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticies and evaluation of drug release behaviors in vitro/in vivo, ” J. Mat. Sci.: Mat. Med., 17(6): 509-16 (2006).

Yu, et al., “Engineered bio-nanocapsules, the selective vector for drug delivery system”, IUBMB Like, 58(1): 1-6 (2006).

Yuan, et al. ‘Intranasal Immunization with Chitosan/pCETP Nanoparticies Inhibits Atherosclerosis in a Rabbit Model of Atherosclerosis’ Vaccine. 26(29-30): 3727-3734 (2008).

Yuan, et al., “siRNA Selection Server: an automated siRNA oligonucleotide prediction server. ”, Nucl. Acids. Res., 32: W130-W134 (2004).

Zamore, et al., “RNAi: double-stranded RNA directs the ATP- dependent cleavage of mRNA at 21 to 23 nucleotide intervals. ”, Cell, 101(l): 25-33 (2000).

Zauner, et al., “Polylysine-basedtransfection systems utilizing receptor-mediated delivery. ”, Adv. Drug Del. Rev., 30: 97-113 (1998).

Zhang, et al., “The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK”, The Prostate, 68(5): 508-516 (2008).

Zheng, et al., “Highly fluorescent, water-soluble, size-tunable gold quantum dots. ”, Phys. Rev. Lett., 93(7): 077402 (2004).

Zhou, et al., “Investigation on a novel core-coated microspheres protein delivery system. ”, J. Control. Release, 75(l-2): 27-36 (2001).

Zhou, et al., “NAAG peptidase inhibitors and their potential for diagnosis and therapy”, Nature Rev. Drug Disc., 4: 1015-26 (2005). Zhou, et al., “Preparation of poly(L-serine ester): a structural analog of conventional poly(L-serine)”, Macromolecules, 23(14): 3399- 3406 (1990).

Zuker, “Mfold web server for nucleic acid folding and hybridization prediction”, Nuc. Acid. Res., 31: 3406-3415 (2003).

⇐ Предыдущая 1 2 345 6 7 8 9 10 Следующая ⇒